Interferon alfa-2b human recombinant + Diphenhydramine (Interferonum alpha-2b + Diphenhydraminum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Ophthalmic products

Interferons

Included in the formulation
  • Ophthalmoferon
    drops d / eye 
    FIRN M, ZAO     Russia
    • АТХ:

    S.01.A.D.05   Interferon

    Pharmacodynamics:

    Interferon alfa-2b inhibits the replication of viruses, disrupts the synthesis of viral DNA, RNA and viral proteins. The drug increases the phagocytic activity of macrophages, potentiates the cytotoxic effect of lymphocytes. It shows pronounced antitumor activity due to antiproliferative properties.

    Diphenhydramine blocks histamine H1-receptors and eliminates the effects of histamine mediated through this type of receptor. Has anti-allergic, ganglion-blocking, local anesthetic and antispasmodic effect.

    Reduces or prevents spasm caused by histamine smooth muscle, increased capillary permeability, tissue swelling, pruritus and flushing. Antagonism with histamine is manifested to a greater extent in relation to local vascular reactions in inflammation and allergies. Causes local anesthesia (when ingested, there is a brief sensation of numbness in the mucous membranes of the mouth).

    Pharmacokinetics:

    When used locally, the drug is not subject to systemic absorption.The concentration of active substances reached in the blood is well below the detection limit (the limit of determination of interferon alfa-2b-1-2 IU/ ml) and has no clinical significance. Information on the degree of penetration of diphenhydramine into various tissues of the eye after topical application is not present.

    Indications:

    - adenoviral, hemorrhagic (enterovirus), herpetic conjunctivitis;

    - adenoviral, herpetic (vesicular, spot, tree, kartobrazny) keratitis;

    - herpetic stromal keratitis with ulceration of the cornea and without ulceration;

    - adenoviral and herpetic keratoconjunctivitis;

    - herpetic uveitis and keratouveitis (with and without ulceration);

    - dry eye syndrome;

    - prevention of graft disease and prevention of recurrence of herpetic keratitis after keratoplasty;

    - prevention and treatment of complications after excimer laser refractive surgery of the cornea.

    ICD-10

    I.B00-B09.B00.5   Herpetic eye disease

    I.B25-B34.B30.0   Keratoconjunctivitis caused by adenovirus (H19.2 *)

    I.B25-B34.B30.1   Conjunctivitis caused by adenovirus (H13.1 *)

    I.B25-B34.B30.3   Acute epidemic hemorrhagic conjunctivitis (enterovirus) (H13.1 *)

    V.F50-F59.F51.2   Sleep and wakefulness disorder inorganic etiology

    VII.H00-H06.H04.1   Other diseases of the lacrimal gland

    VII.H15-H22.H16   Keratite

    VII.H15-H22.H16.0   Corneal ulcer

    VII.H15-H22.H16.2   Keratoconjunctivitis

    VII.H15-H22.H19.1 *   Keratitis due to herpes simplex virus, and keratoconjunctivitis (B00.5 +)

    VII.H15-H22.H19.2 *   Keratitis and keratoconjunctivitis in other infectious and parasitic diseases classified elsewhere

    VII.H15-H22.H20   Iridocyclitis

    VII.H55-H59.H59   Lesions of the eye and its adnexa after medical procedures

    VIII.H80-H83.H81   Violations of the vestibular function

    VIII.H80-H83.H81.0   Ménière's disease

    X.J30-J39.J30.0   Vasomotor rhinitis

    X.J30-J39.J30.1   Allergic rhinitis caused by pollen of plants

    X.J30-J39.J30.3   Other allergic rhinitis

    XII.L20-L30.L20.8   Other atopic dermatitis

    XII.L20-L30.L23   Allergic contact dermatitis

    XII.L20-L30.L24   Simple irritant contact dermatitis

    XII.L20-L30.L29   Itching

    XII.L50-L54.L50   Hives

    XXI.Z40-Z54.Z51.4   Preparatory procedures for subsequent treatment, not elsewhere classified

    XXI.Z80-Z99.Z94.7   Presence of transplanted cornea

    Contraindications:

    Closed-angle glaucoma, individual intolerance of the drug components.

    Carefully:

    Pregnancy, tobreast-feeding.

    Pregnancy and lactation:

    The use of the drug during pregnancy and lactation is possible only for the doctor's prescription if the expected effect exceeds the risk of complications in the fetus and the newborn.

    Dosing and Administration:

    Conjunctival.

    With viral eye lesions in adults and children in acute stages of the disease, the drug is instilled into the conjunctival sac by 1-2 drops up to 6-8 times a day. As the inflammation slows down, the number of instillations is reduced to 2-3 times a day, until the symptoms disappear.

    With the "dry" eye syndrome, the drug is used daily, digging into the diseased eye 1-2 drops 2 times a day for 25-30 days, until the symptoms disappear.

    For the prevention and treatment of complications after excimer laser refractive surgery of the cornea, the drug is used daily, starting from the day of operation, by instilling 1-2 drops into the eye 2 times a day for 10 days.

    To prevent graft disease and prevent the recurrence of herpetic keratitis after keratoplasty, the drug is used daily by digesting 1-2 drops into the operated eye 3-4 times a day during the first 2 weekspruce after surgery.

    Side effects:

    Not noted.

    Overdose:

    Cases of drug overdose have not been identified.

    Interaction:

    The drug is compatible and well combined with anti-inflammatory, antibacterial, corticosteroid, reparative ophthalmic forms medicines and preparations of tear-replacement therapy.

    Special instructions:

    Patients using contact lenses should instill the drug only with the lenses removed and can wear them 15-20 minutes after instillation of the drug.

    Influence on the ability to drive vehicles and work with machinery. Immediately after instillation, blurring of visual perception is possible, therefore it is recommended to start the management of vehicles or work with the mechanisms a few minutes after instillation of the drug.

    Instructions
    Up